HRHalla Mohamed Ragab

Halla Mohamed Ragab

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Halla Mohamed Ragab has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Soluble CD163 impact as a prognostic biomarker in chronic lymphocytic leukemia

    by Halla Ragab, Hanaa Attia, Nabila Maksoud, Mona Ibrahim, Mai Mohamed, Abdelkarim Kamel, Mohamed Sobeih, Mohamed Kamal, Wafaa Abd Elaziz

    Chronic lymphocytic leukemia (CLL) is a malignant blood disorder in which there is an excess of white blood cells (lymphocytes) in blood and lymphoid tissues. CLL patients experience different clinical behaviors with diversity in disease course and outcome. Accordingly, prognostic markers are crucial for employing appropriate therapy protocols. CD163 (cluster of differentiation 163) is a monocyte/macrophage receptor. Soluble CD163 (sCD163) is an emerging prognostic player in the field of hematopoietic neoplasms. This study aimed to assess the prognostic potential of sCD163 as a serological marker in CLL. The study included 41 CLL patients and 44 apparently normal healthy volunteers as controls. Expression of CD38 and cytoplasmic ZAP 70 in CLL cells was assessed using flow cytometry. Beta 2 microglobulin (B2M), sCD23, and sCD163 serological markers were measured by ELISA. Serum levels of sCD163 were statistically significantly higher in CLL cases compared to controls (p=0.000). sCD163 levels were positively correlated with absolute lymphocyte count, sCD23, and B2M levels (p= 0.027, p=0.01, and p=0.004, respectively). In conclusion, levels of sCD163 in CLL is a promising prognostic tool for evaluating disease progression.


  • Association between CD3 as a sensitive T cells lineage marker and NAFLD

    by Halla Mohamed Ragab, Nabila Abd El Maksoud, Mona A. Amin, Abdelkarim Kamel, May Fawzi, Wafaa Abd Elaziz

    CD3 antigen represents the most specific as well the most sensitive T cells lineage marker, including NK and NKT. Aim and methods: our study was to evaluate CD-3 in nonalcoholic steatohepatitis patients as a diagnostic and prognostic marker in such patients. Serum samples were collected from 41 NAFLD patients, in addition to 14 healthy subjects. They were recruited from the internal medicine department - Cairo University. All patients and controls were subjected to clinical assessment, abdominal ultrasound examination, laboratory assessment including liver function and enzymes, kidney function, and lipid profile. Fib-4 and NAFLD fibrosis score were calculated for all patients. Also, serum levels of CD-3 were detected by ELISA technique. Results: The NAFLD patients group was divided into three groups: fifteen obese patients, fourteen diabetic patients, twelve obese patients with T2DM. BMI, HbA1C, and cholesterol levels were significantly elevated in the NAFLD cases compared with healthy controls (p<0.05). The mean serum level of CD3 was 64.53±84 ng/ml in NAFLD cases vs. 4.76±2.94 ng/ml in controls. Overall, there was a statistically significant increase in serum CD3 levels in NAFLD cases (p<0.001). Additionally, serum level of CD3 was significantly higher in the diabetic non-obese subjects and obese non-diabetic subjects when compared with the lean subjects (89.4±113.53 ng/ml and 60.91±73.76 vs. 4.76±2.94 ng/ml, P = 0. 003& 0.05; respectively. Conclusion: Serum level of CD3 can be used as a prognostic marker in cases with NAFLD as they increase with the progression of the disease and is correlated with fibrosis stage.

  • Open Access

    CD24 Gene Expression as a Risk Factor for Non-Alcoholic Fatty Liver Disease

    by Mona A. Amin, Halla M. Ragab, Nabila Abd El Maksoud, Wafaa Abd Elaziz

    In light of increasing NAFLD prevalence, early detection and diagnosis are needed for decision-making in clinical practice and could be helpful in the management of patients with NAFLD. The goal of this study was to evaluate the diagnostic accuracy of CD24 gene expression as a non-invasive tool to detect hepatic steatosis for diagnosis of NAFLD at early stage. These findings will aid in the creation of a viable diagnostic approach. Methods: This study enrolled eighty individuals divided into two groups; a study group included forty cases with bright liver and a group of healthy subjects with normal liver. Steatosis was quantified by CAP. Fibrosis assessment was performed by FIB-4, NFS, Fast-score, and Fibroscan. Liver enzymes, lipid profile, and CBC were evaluated. Utilizing RNA extracted from whole blood, the CD24 gene expression was detected using real-time PCR technique. Results: It was detected that expression of CD24 was significantly higher in patients with NAFLD than healthy controls. The median fold change was 6.56 higher in NAFLD cases compared to control subjects. Additionally, CD24 expression was higher in cases with fibrosis stage F1 compared to those with fibrosis stage F0, as the mean expression level of CD24 was 7.19 in F0 cases as compared to 8.65 in F1 patients but without significant difference (p = 0.588). ROC curve analysis showed that CD24 ∆CT had significant diagnostic accuracy in the diagnosis of NAFLD (p = 0.034). The optimum cutoff for CD24 was 1.83 for distinguishing patients with NAFLD from healthy control with sensitivity 55% and specificity 74.4%; and an area under the ROC curve (AUROC) of 0.638 (95% CI: 0.514–0.763) was determined. Conclusion: In the present study, CD24 gene expression was up-regulated in fatty liver. Further studies are required to confer its diagnostic and prognostic value in the detection of NAFLD, clarify its role in the progression of hepatocyte steatosis, and to elucidate the mechanism of this biomarker in the progression of disease.


  • Open Access

    Significance of MiRNA-34a and MiRNA-192 as a risk factor for nonalcoholic fatty liver disease

    by Halla M. Ragab, Wafaa M. Ezzat, Eman Mahmoud Hassan, Nabila Abd El Maksoud, Mie Afify, Mohamed D. E. Abd El-Maksoud, Wafaa Abd Elaziz


  • Open Access

    Complement C3 as a potential NAFLD predictor in an Egyptian cohort with diabetes and/or obesity

    by Halla M. Ragab, Nabila Abd El Maksoud, Mona A. Amin, Wafaa Abd Elaziz

    Complement system is becoming increasingly recognized as being intimately tied to obesity and other various metabolic abnormalities linked to it and may be involved in NAFLD. The goal of this study was to see if complement C3 might be used as a diagnostic and prognostic marker in NAFLD patients. Forty-one NAFLD patients and fourteen age- and gender-matched control individuals were enrolled in this study. All subjects were subjected to abdominal ultrasound examination and clinical assessment with special emphasis on the liver function enzymes, blood glucose levels, lipid profile, and kidney function tests. Non-invasive assessment of hepatic steatosis and fibrosis has evolved using serology-based scoring systems such as the Fibrosis-4 score and NAFLD Fibrosis Score (NFS). Additionally, serum levels of complement C3 were determined by the ELISA method. In this study, BMI, cholesterol, triglyceride levels, and NFS were all substantially higher in NAFLD patients compared to healthy controls. Moreover, complement C3 was considerably higher in NAFLD cases (1.52±0.29 g/L) vs. healthy controls (0.93±0.289 g/L) (p<0.001). Compared to lean people (0.93±0.29 g/L), the mean complement C3 levels were significantly higher in obese diabetes (1.69±0.29 g/L), obese non-diabetic (1.48±0.174 g/L), and diabetic non-obese patients (1.36±0.28 g/L). Using a cutoff for complement C3 1.135 (g/L) for distinguishing NAFLD patients from healthy controls has a sensitivity of 90.2% and specificity of 78.6%. In conclusion, serum complement C3 may be useful in the identification of fibrosis in non-alcoholic fatty liver disease. Moreover, complement C3 may be a promising tool for predicting the worsening of liver inflammation.


  • Open Access

    Clinical Significance of Serum CD14 and Its Polymorphism as a Biomarker of Non-Alcoholic Fatty Liver Disease

    by Mona A. Amin, Halla M. Ragab, Nabila Abd El Maksoud, Wafaa Abd Elaziz

    Background: Liver inflammation is deliberated a risk factor for the ongoing liver damage including non-alcoholic steatohepatitis, cirrhosis, and hepatoma. CD14, an effectual mediator for the monocytes activation, has been postulated as a marker of liver inflammation and fibrosis. This study is constructed to detect the alterations in the CD14 serum levels in 40 NAFLD cases and 14 healthy controls along with to analyze the role of CD14 polymorphisms in the causation and severity of Non-Alcoholic Fatty Liver Disease (NAFLD). Liver enzymes, glycated hemoglobin, together with lipid profile were estimated in all included subjects. The diagnosis of NAFLD depends largely on ultrasonography. NAFLD fibrosis score and FIB-4 score were calculated. Serum CD14 was quantified by EnzymeLinked Immunosorbent Assay (ELISA) and C14-159C/T SNP was genotyped via Polymerase Chain Reaction (PCR) and Restriction Fragment Length Polymorphisms (RFLP). Results: Serum CD14 was markedly higher in the diabetic subjects either lean or overweight/obese than the controls (P0.676 (P=1.000). Conclusion: The former observations advocate the potential role of CD14 in both the pathogenesis and progression of NAFLD. Yet, it didn't correlate with the NFS, consequently it couldn't forecast the severity of the disease. Furthermore, no association was distinguished linking CD14 C-(159) T polymorphism and the risk of NAFLD occurrence.

  • Performance of serum CD163 as a marker of fibrosis in patients with NAFLD

    by Halla M. Ragab, Nabila Abd El Maksoud, Mona A. Amin, Wafaa Abd Elaziz


  • Combination of Serum Survivin and AFP as a Potential Marker in HCC Associated with Hepatitis C Viral Infection

    by Halla Mohamed Ragab, Nabila Abd El Maksoud, Wafaa Abd Elaziz, Mohab H. Halim, Abdelkarim Kamel, Nour A. Abdulla

    Combination of Serum Survivin and AFP as a Potential Marker in HCC Associated with Hepatitis C Viral Infection

  • Open Access

    Assessment of Ki-67 as a potential biomarker in patients with breast cancer

    by Halla Mohamed Ragab, Nervana Samy, Mie Afify, Nabila Abd El Maksoud, HebatAllah Mohamed Shaaban


  • Open Access

    Significance of growth differentiation factor 15 in chronic HCV patients

    by Mohab H. Halim, Nour A. Abdulla, Abdelkarim Kamel, Nabila Abd El Maksoud, Halla M. Ragab